GRI
GRI Bio Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.32M
P/E Ratio
—
EPS
$-116.75
Beta
-1.24
52W High
$80.36
52W Low
$2.10
50-Day MA
$2.72
200-Day MA
$31.24
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About GRI Bio Inc.
GRI Bio Inc. is a cutting-edge biotechnology company focused on revolutionizing patient care through its proprietary microbiome technology platform. With a strong emphasis on developing innovative therapies specifically targeting unmet medical needs in immunology and oncology, GRI Bio strives to tackle the underlying causes of diseases rather than just their symptoms. The company has established a robust pipeline of product candidates and strategic research partnerships, positioning it for notable growth and a leadership role in the burgeoning field of microbiome therapeutics. Committed to enhancing patient outcomes, GRI Bio is well-equipped to make significant contributions to the future of healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.97M |
| Operating Margin | 0.00% |
| Return on Equity | -238.20% |
| Return on Assets | -103.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $12.07 |
| Price-to-Book | 0.57 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $1.45M |
| Float | $1.45M |
| % Insiders | 0.57% |
| % Institutions | 0.15% |
Data last updated: 4/8/2026